Tetraethylammonium

DB08837InvestigationalSmall molecule

Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now... As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide.

Mechanism: Tetraethylammonium's mechanism of action is still being investigated, but it is known that it blocks autonomic ganglia, calcium- and voltage- activated potassium channels, and nicotinic acetylcholine receptors.
Curator reviewed
Primary indication: Tetraethylammonium is an experimental drug with no approved indication.Curator reviewed · 1 structured indication
Formula / weight: C₈H₂₀N · 130.2511 g/mol (avg)
Code names: NSC-102778 · NSC-156315

What you can answer from here — as of September 12, 2026

15Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7TransportersSubstrate / inhibitor direction, not just membership

Listed above

6Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

1Marketed productAcross 1 country and 1 labeller

36+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tetraethylammonium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account